Fungal diseases of the nail bed (onychomycosis) and epidermis are recurrent illnesses in the elderly and immunocompromised patients, which have few efficacious treatment options. Current treatment options for onychomycosis are limited to topical agents, laser treatment, and oral antifungals. Previous generations of topical agents were not efficacious, owing to poor penetration of the nail bed. Oral antifungal drugs, such as itraconazole, terbinafine, and fluconazole, not only give better response rates but also inhibit a host of CYP450 enzymes. Oral antifungals can exacerbate drug–drug interactions for patients taking other medications concurrently. Newer topical agents might recognize improved efficacy and provide therapeutic alternatives when the use of oral antifungal agents is contraindicated. Recently, the Food and Drug Administration (FDA) approved efinaconazole and tavaborole for the treatment of onychomycosis. Additionally, the FDA approved luliconazole for the treatment of tinea pedis, tinea cruris, and tinea corporis. This review examines the mechanism of action, spectrum of activity, pharmacokinetics, and clinical trials data and considers the place in therapy for these 3 new antimycotic agents.
GhannoumMAHajjehRAScherR. A large-scale North American study of fungal isolates from nails: the frequency of onychomycosis, fungal distribution, and antifungal susceptibility patterns. J Am Acad Dermatol. 2000;43(4):641–648.
HayetteMPSacheliR. Dermatophytosis, trends in epidemiology and diagnostic approach. Current Fungal Infection Reports [Internet]. 2015;9(3):164–179. Web site. http://link.springer.com/10.1007/s12281-015-0231-4. Accessed April 1, 2016.
5.
OdomR. Pathophysiology of dermatophyte infections. J Am Acad Dermatol. 1993;28(5 pt 1):S2–S7.
6.
CarrollKCHobdenJAMillerS. Medical Mycology. Jawetz, Melnick, & Adelberg’s Medical Microbiology, 27e [Internet]. New York, NY: McGraw-Hill Education; 2015. Web site. http://mhmedical.com/content.aspx?aid=1114738831. Accessed April 1, 2016.
AmeenMLearJTMadanV. British Association of Dermatologists’ guidelines for the management of onychomycosis 2014. Br J Dermatol [Internet]. 2014;171(5):937–958. Web site. http://dx.doi.org/10.1111/bjd.13358. Accessed April 1, 2016.
12.
JiaravuthisanMMSassevilleDVenderRB. Psoriasis of the nail: anatomy, pathology, clinical presentation, and a review of the literature on therapy. J Am Acad Dermatol [Internet]. 2007;57(1):1–27. Web site. http://www.sciencedirect.com/science/article/pii/S0190962205032287. Accessed April 1, 2016.
13.
ThomasJJacobsonGANarkowiczCK. Toenail onychomycosis: an important global disease burden. J Clin Pharm Ther. 2010;35(5):497–519.
14.
KatohT. Guidelines for diagnosis and treatment of mucocutaneous candidiasis. Jpn J Med Mycol. 2009;50(4):207–212.
15.
IorizzoMPiracciniBMRechG. Treatment of onychomycosis with oral antifungal agents. Expert Opin Drug Deliv. 2005;2(3):435–440.
16.
StüttgenGBauerE. Bioavailability, skin- and nailpenetration of topically applied antimycotics. Mycoses [Internet]. Blackwell Publishing Ltd; 1982;25(2):74–80. Web site. http://dx.doi.org/10.1111/j.1439-0507.1982.tb02721.x. Accessed April 1, 2016.
17.
Anacor Pharmaceuticals Inc. Kerydin [package insert]. Palo Alto, CA; 2014.
18.
BakerSJZhangY-KAkamaT. Discovery of a new boron-containing antifungal agent, 5-fluoro-1,3-dihydro-1-hydroxy-2,1-benzoxaborole (AN2690), for the potential treatment of onychomycosis. J Med Chem [Internet]. American Chemical Society. 2006;49(15):4447–4450. Web site. http://0-pubs.acs.org.libcat.ferris.edu/doi/abs/10.1021/jm0603724. Accessed April 1, 2016.
19.
BenkovicSJBakerSJAlleyMRK. Identification of borinic esters as inhibitors of bacterial cell growth and bacterial methyltransferases, CcrM and MenH. J Med Chem. 2005;48(23):7468–7476.
20.
Pharmacyclics Inc. Prescribing Information. 2014.
21.
ElewskiBEAlyRBaldwinSL. Efficacy and safety of tavaborole topical solution, 5%, a novel boron-based antifungal agent, for the treatment of toenail onychomycosis: results from 2 randomized phase-III studies. J Am Acad Dermatol [Internet]. 2015;1–8. Web site. http://linkinghub.elsevier.com/retrieve/pii/S0190962215015121. Accessed April 1, 2016.
ElsayedMM. Development of topical therapeutics for management of onychomycosis and other nail disorders: a pharmaceutical perspective. J Control Release [Internet]. ElsevierB.V. 2015;199:132–144. Web site. http://linkinghub.elsevier.com/retrieve/pii/S0168365914007652. Accessed April 1, 2016.
TatsumiYYokooMArikaT. In vitro antifungal activity of KP-103, a novel triazole derivative, and its therapeutic efficacy against experimental plantar tinea pedis and cutaneous candidiasis in guinea pigs. Antimicrob Agents Chemother [Internet]. 2001;45(5):1493–1499. Web site. http://aac.asm.org/content/45/5/1493.long. Accessed April 1, 2016.
26.
KogaHNanjohYInoueK. In vitro activities of antifungal drugs against clinical isolates of trichophyton tonsurans. Nihon Ishinkin Gakkai Zasshi. 2006;47(4):299–304.
27.
SugiuraKSugimotoNHosakaS. The low keratin affinity of efinaconazole contributes to its nail penetration and fungicidal activity in topical onychomycosis treatment. Antimicrob Agents Chemother [Internet]. 2014;58(7):3837–342. Web site. http://aac.asm.org/cgi/doi/10.1128/AAC.00111-14. Accessed April 1, 2016.
28.
NiwanoYKuzuharaNKodamaH. In vitro and in vivo antidermatophyte activities of NND-502, a novel optically active imidazole antimycotic agent. Antimicrob Agents Chemother [Internet]. 1998;42(4):967–970. Web site. http://aac.asm.org/content/42/4/967.long. Accessed April 1, 2016.
HuiXBakerSJWesterRC. In Vitro penetration of a novel oxaborole antifungal (AN2690) into the human nail plate. J Pharm Sci [Internet]. 2007;96(10):2622–2631. Web site. http://www.ncbi.nlm.nih.gov/pubmed/17621679. Accessed April 1, 2016.
31.
ElewskiBEAlyRBaldwinSL. Efficacy and safety of tavaborole topical solution, 5%, a novel boron-based antifungal agent, for the treatment of toenail onychomycosis: results from 2 randomized phase-III studies. J Am Acad Dermatol [Internet]. 2015;73(1):62–69. Web site. http://www.sciencedirect.com/science/article/pii/S0190962215015121. Accessed April 1, 2016.
32.
TatsumiYNagashimaMShibanushiT. Mechanism of action of efinaconazole, a novel triazole antifungal agent. Antimicrob Agents Chemother. 2013;57(5):2405–249.
33.
JonesTTavakkolA. Safety and tolerability of luliconazole solution 10-percent in patients with moderate to severe distal subungual onychomycosis. Antimicrob Agents Chemother [Internet]. 2013;57(6):2684–2689. Web site. http://aac.asm.org/content/57/6/2684.short. Accessed April 1, 2016.
34.
WatanabeSTakahashiHNishikawaT. Dose-finding comparative study of 2 weeks of luliconazole cream treatment for tinea pedis—comparison between three groups (1%, 0.5%, 0.1%) by a multi-center randomised double-blind study. Mycoses [Internet]. 2007;50(1):35–40. Web site. http://www.ncbi.nlm.nih.gov/pubmed/17302746. Accessed April 1, 2016.
GuptaAKSimpsonFC. Efinaconazole (Jublia) for the treatment of onychomycosis. Expert Rev Anti Infect Ther. 2014;12(7):743–752.
37.
GhannoumMALongLKimHG. Efficacy of terbinafine compared to lanoconazole and luliconazole in the topical treatment of dermatophytosis in a guinea pig model. Med Mycol. 2010;48(3):491–497.
38.
Jo SiuWJTatsumiYSendaH. Comparison of in vitro antifungal activities of efinaconazole and currently available antifungal agents against a variety of pathogenic fungi associated with onychomycosis. Antimicrob Agents Chemother [Internet]. 2013;57(4):1610–1616. Web site. http://www.ncbi.nlm.nih.gov/pubmed/23318803. Accessed April 1, 2016.
SakamotoMSugimotoNKawabataH. Transungual delivery of efinaconazole: its deposition in the nail of onychomycosis patients and in vitro fungicidal activity in human nails. J Drugs Dermatol. 2014;13(11):1388–1392.
41.
Valeant Pharmaceuticals North America LLC. Jublia [package insert]. Bridgewater, NJ; 2014.
42.
ElewskiBERichPPollakR. Efinaconazole 10% solution in the treatment of toenail onychomycosis: two phase III multicenter, randomized, double-blind studies. J Am Acad Dermatol [Internet]. 2013;68(4):600–608. Web site. http://www.ncbi.nlm.nih.gov/pubmed/23177180. Accessed April 1, 2016.
KogaHTsujiYInoueK. In vitro antifungal activity of luliconazole against clinical isolates from patients with dermatomycoses. J Infect Chemother [Internet]. 2006;12(3):163–165. Web site. http://www.ncbi.nlm.nih.gov/pubmed/16826352. Accessed April 1, 2016.
45.
ScherRKNakamuraNTavakkolA. Luliconazole: a review of a new antifungal agent for the topical treatment of onychomycosis. Mycoses [Internet]. 2014;57(7):389–393. Web site. http://www.ncbi.nlm.nih.gov/pubmed/24621346. Accessed April 1, 2016.
46.
UchidaKNishiyamaYYamaguchiH. In vitro antifungal activity of luliconazole (NND-502), a novel imidazole antifungal agent. J Infect Chemother [Internet]. 2004;10(4):216–219. Web site. http://www.ncbi.nlm.nih.gov/pubmed/15365862. Accessed April 1, 2016.
47.
KogaHNanjohYKanedaH. Short-term therapy with luliconazole, a novel topical antifungal imidazole, in guinea pig models of tinea corporis and tinea pedis. Antimicrob Agents Chemother. 2012;56(6):3138–3143.
48.
WatanabeSTakahashiHNishikawaT. A comparative clinical study between 2 weeks of luliconazole 1% cream treatment and 4 weeks of bifonazole 1% cream treatment for tinea pedis. Mycoses. 2006;49(3):236–241.
49.
WiederholdNPFothergillAWMcCarthyDI. Luliconazole demonstrates potent in vitro activity against dermatophytes recovered from patients with onychomycosis. Antimicrob Agents Chemother. 2014;58(6):3553–3555.
50.
ElyJWRosenfeldSStoneMS. Diagnosis and management of tinea infections. Am Fam Physician [Internet]. 2014;90(10):702–710. Web site. http://www.aafp.org/afp/2014/1115/p702.html. Accessed April 1, 2016.
51.
El-GoharyMvan ZuurenEJFedorowiczZ. Topical antifungal treatments for tinea cruris and tinea corporis. Cochrane Database Syst Rev [Internet]. 2014;8:CD009992. Web site. http://www.ncbi.nlm.nih.gov/pubmed/25090020. Accessed April 1, 2016.
52.
WesterbergDPVoyackMJ. Onychomycosis: current trends in diagnosis and treatment. Am Fam Physician. 2013;88(11):762–770.
53.
GuptaAKRyderJEJohnsonAM. Cumulative meta-analysis of systemic antifungal agents for the treatment of onychomycosis. Br J Dermatol [Internet]. Blackwell Science Ltd; 2004;150(3):537–544. Web site. http://dx.doi.org/10.1046/j.1365-2133.2003.05728.x. Accessed April 1, 2016.
